Indicators
Indicators
Value
Direction
MACD(12,26,9)
-6.633
Neutral
RSI(14)
49.110
Neutral
STOCH(KDJ)(9,3,3)
25.415
Neutral
ATR(14)
22.471
High Vlolatility
CCI(14)
-119.098
Sell
Williams %R
70.771
Sell
TRIX(12,20)
0.086
Sell
StochRSI(14)
29.415
Buy
Search
Madrigal Pharmaceuticals Inc
MDGLAdd to Watchlist
518.250USD
+7.990+1.57%
Market hours （ET）Quotes delayed by 15 min
11.94BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Madrigal Pharmaceuticals Inc
Currency: USD Updated: 2026-05-12Key Insights
Madrigal Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 12 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 677.22.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Madrigal Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Madrigal Pharmaceuticals Inc Highlights
StrengthsRisks
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Undervalued
The company’s latest PE is -37.43, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 24.02M shares, decreasing 0.68% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 127.00 shares of this stock.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
415.786
Target Price
+25.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-12The current financial score of Madrigal Pharmaceuticals Inc is 8.13, ranking 46 out of 383 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 311.34M, representing a year-over-year increase of 126.84%, while its net profit experienced a year-over-year increase of 28.88%.
Score
Financials
6.16
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.38
Operational Efficiency
8.30
Growth Potential
9.36
Shareholder Returns
7.46
Madrigal Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2026-05-12The current valuation score of Madrigal Pharmaceuticals Inc is 7.21, ranking 141 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -37.43, which is -88.20% below the recent high of -4.42 and -24.73% above the recent low of -46.69.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 12/383
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-12The current earnings forecast score of Madrigal Pharmaceuticals Inc is 8.12, ranking 159 out of 383 in the Biotechnology & Medical Research industry. The average price target is 557.00, with a high of 650.00 and a low of 456.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
677.217
Target Price
+32.78%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Madrigal Pharmaceuticals Inc
MDGL
17
CRISPR Therapeutics AG
CRSP
29
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-12The current price momentum score of Madrigal Pharmaceuticals Inc is 7.02, ranking 145 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 549.46 and the support level at 480.59, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
518.384
Sell
MA10
516.274
Buy
MA20
519.497
Sell
MA50
493.500
Buy
MA100
501.137
Buy
MA200
476.067
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-12The current institutional shareholding score of Madrigal Pharmaceuticals Inc is 10.00, ranking 1 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 104.16%, representing a quarter-over-quarter increase of 8.16%. The largest institutional shareholder is John Paulson, holding a total of 1.71M shares, representing 7.41% of shares outstanding, with 22.11% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Baker Bros. Advisors LP
RTW Investments L.P.
Avoro Capital Advisors LLC
Janus Henderson Investors
BlackRock Institutional Trust Company, N.A.
SQN, L.L.C.
State Street Investment Management (US)
1
2
Risk Assessment
Currency: USD Updated: 2026-05-12The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Madrigal Pharmaceuticals Inc is 7.08, ranking 17 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is -1.07. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
-1.07
VaR
+5.27%
240-Day Maximum Drawdown
+29.36%
240-Day Volatility
+51.39%
Return
Best Daily Return
60 days
+12.30%
120 days
+12.30%
5 years
+268.07%
Worst Daily Return
60 days
-11.11%
120 days
-11.11%
5 years
-13.32%
Sharpe Ratio
60 days
+0.88
120 days
+0.05
5 years
+0.61
Risk Assessment
Maximum Drawdown
240 days
+29.36%
3 years
+47.88%
5 years
+61.41%
Return-to-Drawdown Ratio
240 days
+3.01
3 years
+0.91
5 years
+1.58
Skewness
240 days
+0.83
3 years
+0.84
5 years
+25.45
Volatility
Realised Volatility
240 days
+51.39%
5 years
+81.25%
Standardised True Range
240 days
+3.78%
5 years
+2.38%
Downside Risk-Adjusted Return
120 days
+7.16%
240 days
+7.16%
Maximum Daily Upside Volatility
60 days
+57.16%
Maximum Daily Downside Volatility
60 days
+34.26%
Liquidity
Average Turnover Rate
60 days
+1.57%
120 days
+1.52%
5 years
--
Turnover Deviation
20 days
-23.52%
60 days
-4.31%
120 days
-6.98%
Peer Comparison
Biotechnology & Medical Research
Madrigal Pharmaceuticals Inc
MDGL
7.85 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
